Jim Cramer's Stop Trading: Consider Buying Celgene on Friday

NEW YORK (TheStreet) -- Shares of Celgene (CELG) are lower by roughly 4% despite the company beating on top and bottom line estimates and issuing strong guidance. 

On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said the biotech company's management almost always provides conservative guidance. 

"This company has a lot of earnings power. They've got a lot of new drugs," he added. 

The stock will likely be a down a couple of percentage points on Friday. If so, that's when investors should consider buying, Cramer concluded.


-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Three Stocks That Have My Attention

Three Stocks That Have My Attention

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Corporate America Is Sitting on $5 Trillion of M&A Firepower

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices